Please provide your email address to receive an email when new articles are posted on . Kim’s hypothesis arises partially from studies that showed that C3, when introduced to synthetic neutrophils, ...

Researchers describe pegcetacoplan, a new class of medication, as the “closest thing to a cure” for the rare, severe kidney disease C3 glomerulopathy.

With Alzheimer’s disease therapies finally reaching the market and hundreds of active clinical trials for therapies and diagnostics, it seems like every week brings another potential avenue to explore ...

The figure focuses on complement activation by means of the alternative pathway because it is the one responsible for hemolysis in PNH. The lightning bolt symbolizes the spontaneous hydrolytic ...

Cold agglutinin disease is a rare autoimmune hemolytic anemia characterized by hemolysis that is caused by activation of the classic complement pathway. Sutimlimab, a humanized monoclonal antibody, ...

– First patient dosed in Phase 2 study of ANX005 C1q targeted mAb – “Huntington’s Disease is a devastating, progressive movement disorder with no cure and no approved therapeutic options available to ...

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company’s investigational RNA ...

These findings suggest complement protein levels may be an important biomarker for type 1 diabetes. Disruption of the complement system appears to precede the onset of islet autoimmunity (IA), making ...